This clinical trial is focused on studying a condition called X-linked Retinitis Pigmentosa, which is a genetic disorder that leads to a gradual loss of vision. This condition is caused by mutations in the RPGR gene. The study aims to evaluate the long-term safety and effectiveness of a gene therapy treatment known as AAV5-hRKp.RPGR. This treatment involves delivering a modified virus to the retina, the part of the eye that senses light, to help improve vision in individuals affected by this genetic condition.

Participants in this study will receive the gene therapy treatment through a procedure called subretinal injection, where the solution is injected under the retina. The study will monitor the participants over an extended period to assess how well the treatment works and to ensure it is safe. The main focus will be on changes in vision and any side effects that may occur. The study will also involve the use of other medications, such as Omeprazole, which may be recommended for participants with certain risk factors, and Cefazolin Sodium, Vancomycin, and Cefuroxime, which are antibiotics used to prevent infections during eye surgeries. Additionally, Triamcinolone Acetonide, Dexamethasone Acetate, and Betamethasone are corticosteroids that may be used to reduce inflammation after surgery.

The purpose of this study is to gather information on how well the gene therapy works in improving vision and to monitor any potential side effects over time. Participants will be followed up regularly to check their vision and overall health. This study is part of a larger effort to find effective treatments for genetic eye conditions and to improve the quality of life for those affected by Retinitis Pigmentosa.